Podcasts about readmission

In his weekly clinical update, Dr. Griffin deep dives into whether the mysterious respiratory illness in the Congo is malaria, and in conjunction with your host Vincent Racaniello discusses the failure of the poliovirus eradication campaign with virus circulation detected throughout Europe and how we should focus on disease control not virus circulation, then returns to discussing avian influenza in raw milk and the early stoppage of the mpox antiviral Tecovirimat  before reviewing the recent statistics on SARS-CoV-2 infection, the WasterwaterScan dashboard, if there is a difference in protection against the development of severe disease between an mRNA or a protein based vaccine, where to find PEMGARDA, and information for Columbia Unversity Irving Medical Center's long COVID treatment center. Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode IIs the mysterious disease in the Congo, malaria? (AP News) State of global health, year-end remarks by WHO director-general (WHO) Really, progress towards poliomyelitis eradication? (CDC MMWR) Increases in confirm cases ¹ control of poliomyelitis (WHO) Polio European Union and United Kingdom, is that 1 global entry? (Science) Is the WHO the global CDC?  polio vaccination guidelines (WHO) Do you feed your cats raw milk? (Public Health LA county) Is there avian influenza in the zoo near you? (Maricopa) Don't feed your cat raw milk (CIDRAP) Holy Cow! H5N1 in cows! (microbeTV) Tecovirimat no improvement in Mpox resolution or pain(NIAID NIH) Interim results from STOMP study of  Tecovirimat (SIGA) Trial stops enrollment after Tpoxx fails (CIDRAP) Is Tecovirimat really first-in-class mpox therapy? (Viruses) Influenza weekly surveillance report: clift notes (CDC FluView) US respiratory virus activity (CDC Respiratory Illnesses) Waste water scan for 11 pathogens (WastewaterSCan) RSV-Network (CDC Respiratory Syncytial virus Infection) COVID-19 deaths (CDC) COVID-19 national and regional trends (CDC) Waste water scan for 11 pathogens (WastewaterSCan) COVID-19 variant tracker (CDC) SARS-CoV-2 genomes galore (Nextstrain) Relative effectiveness of homologous NVX-CoV2373 and BNT162b2 COVID-19 vaccinations in South Korea (Vaccine) Phase III trial results! Comparative efficacy and safety of COVID-19 (BMC Infectious Diseases) Where to get pemgarda (Pemgarda) EUA for the pre-exposure prophylaxis of COVID-19 (INVIYD) Fusion center near you….if in NY (Prime Fusions) CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Infectious Disease Society guidelines for treatment and management (ID Society) Drug interaction checker (University of Liverpool) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) What to do when sick with a respiratory virus (CDC) When your healthcare provider is infected/exposed with SARS-CoV-2 (CDC) Managing healthcare staffing shortages (CDC) Stop playing favorites with COVID-19 in healthcare settings (Infection Control & Hospital Epidemiology) Steroids, dexamethasone at the right time (OFID) Anticoagulation guidelines (hematology.org) Remdesivir Effectiveness in Reducing the Risk of 30-day Readmission in Vulnerable Patients Hospitalized for COVID-19 (CID) Daniel Griffin's evidence based medical practices for long COVID (OFID) Long COVID hotline (Columbia : Columbia University Irving Medical Center) Letters read on TWiV 1174 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv

In his weekly clinical update, Dr. Griffin summarizes influenza and RSV circulation in the US, the benefit of administering oseltamivir early and if influenza vaccination reduces secondary household infections, before reviewing the recent statistics on SARS-CoV-2 infection, the WasterwaterScan dashboard, how 1st or 2nd trimester SARS-CoV-2 infections may shorten newborn telomeres, what are B1 cells, if IgG4 responses are critical for protection elicited by mRNA vaccines, if there is a difference in protection against the development of severe disease between an mRNA or a protein based vaccine, where to find PEMGARDA, if remdesivir reduces readmission of vulnerable patients once hospitalized for COVID-19, information for Columbia University Irving Medical Center's long COVID treatment center, if transcutaneous electrical nerve stimulation ameliorates musculoskeletal pain and fatigue during long COVID, do antihistamines reduce post-acute sequelae of SARS-CoV-2 infection and how long can SARS-CoV-2 antigens be detected in blood. Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Influenza weekly surveillance report: cliff notes (CDC FluView) US respiratory virus activity (CDC Respiratory Illnesses) Influenza vaccines protect against secondary infections in households (JAMA Network) Benefit of early oseltamivir therapy for influenza A (CID) RSV-Network (CDC Respiratory Syncytial virus Infection) COVID-19 deaths (CDC) COVID-19 national and regional trends (CDC) Waste water scan for 11 pathogens (WastewaterSCan) COVID-19 variant tracker (CDC) SARS-CoV-2 genomes galore (Nextstrain) Maternal infection of SARS-CoV-2 during 1st and 2nd trimesters newborn telomere shortening (Journal of Translational Medicine) What is a B1 cell? (Wikipedia) Pre-COVID and post-COVID vaccination on long COVID (Journal of Infection) Delayed Induction of Noninflammatory SARS-CoV-2 Spike-Specific IgG4 Antibodies after  BNT162b2 Vaccination in Children (The Pediatric Infectious Disease Journal) Relative effectiveness of homologous NVX-CoV2373 and BNT162b2 COVID-19 vaccinations in South Korea (Vaccine) Phase III trial results! Comparative efficacy and safety of COVID-19 vaccines (BMC Infectious Diseases) Where to get pemgarda (Pemgarda) EUA for the pre-exposure prophylaxis of COVID-19 (INVIYD) Fusion center near you….if in NY (Prime Fusions) CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Infectious Disease Society guidelines for treatment and management (ID Society) Drug interaction checker (University of Liverpool) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) What to do when sick with a respiratory virus (CDC) When your healthcare provider is infected/exposed with SARS-CoV-2 (CDC) Managing healthcare staffing shortages (CDC) Steroids, dexamethasone at the right time (OFID) Anticoagulation guidelines (hematology.org) Remdesivir Effectiveness in Reducing the Risk of 30-day Readmission in Vulnerable Patients Hospitalized for COVID-19 (CID) Daniel Griffin's evidence based medical practices for long COVID (OFID) Long COVID hotline (Columbia : Columbia University Irving Medical Center) Transcutaneous electrical nerve stimulation for fibromyalgia-like syndrome in patients with Long-COVID(Scientific Reports) Mitigating the risks of post-acute sequelae of SARS-CoV-2 infection (PASC) with intranasal chlorpheniramine (BMC Infectious Diseases) Measurement of circulating viral antigens post-SARS-CoV-2 infection (CID) Letters read on TWiV 1172 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv

The Centers for Medicare and Medicaid Services (CMS) measures and, in some cases, penalizes facilities whose inpatient mortality or readmission (up to 3 per cent of their traditional Medicare revenue) rates for pneumonia, heart failure, acute myocardial infarction, and other conditions exceed their established benchmarks. Since these measures are based solely on ICD-10-CM/PCS-based administrative data applied to algorithms developed by Yale University, inaccurate documentation and coding can unwittingly misrepresent a facility's excellent performance resulting in underserved underpayments.  During the next live edition of the long-running Internet broadcast, Talk Ten Tuesday, Dr. James S. Kennedy, president of CDIMD in Nashville, Tenn., will present five relatively simple CDI strategies involving the CMS mortality and readmission measures that, if implemented, will more accurately reflect your facility's excellent performance and lower or eliminate undeserved penalties.  Be sure to take notes and invite your colleagues from quality to listen as well.Also part of the broadcast will be these instantly recognizable panelists, who will report more news during their segments:Social Determinants of Health: Tiffany Ferguson, CEO for Phoenix Medical Management, Inc., will report on the news that is happening at the intersection of medical record auditing and the SDoH.The Coding Report: Christine Geiger, Assistant Vice President of Acute and Post-Acute Coding Services for First Class Solutions, will report on the latest coding news.News Desk: Timothy Powell, ICD10monitor national correspondent and regulatory expert, will anchor the Talk Ten Tuesdays News Desk.TalkBack: Erica Remer, MD, founder and president of Erica Remer, MD, Inc., and Talk Ten Tuesdays co-host, will report on a subject that has caught her attention.

In his weekly clinical update, Dr. Griffin informs us about mpox circulation and new vaccine approval, the Marburg virus outbreak in Rwanda, and the largest outbreak of whooping cough in a decade before reviewing the recent statistics on SARS-CoV-2 infection, the WasterwaterScan dashboard, immunity among those over 65th following the 3rd dose of the COVID-19 mRNA vaccine, where to find PEMGARDA, a reminder of how and when to use steroids to treat COVID-19, how well the SARS-CoV-2 rapid antigen test performed, what do when healthcare workers succumb to SARS-CoV-2 infection, the effect of remdesivir on survival and readmission of hospitalized patients, if cognitive impairment following virus infection impairs one's driving and how long COVID affects Chinese society. Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Undiagnosed MPXV infections are high in men who have sex with men (BMC Infectious Diseases) WHO, now a vaccine approval agency, Jynneos for teens  (CIDRAP) Mpox outbreak global trends (WHO) How to stop Marburg virus (Rwanda Biomedical Centre) Marburg virus fact sheet (Rwanda Biomedical Centre) Largest whooping cough outbreak in US in a decade (NPR) COVID-19 deaths (CDC) COVID-19 national and regional trends (CDC) Waste water scan for 11 pathogens (WastewaterSCan) COVID-19 variant tracker (CDC) SARS-CoV-2 genomes galore (Nextstrain) Insurance relates to effectiveness and waning of immunity following 3rd dose of mRNA COVID-19 vaccine? (JID) New preventive COVID-19 agent (ISDA) IDSA Guidelines on the Treatment and Management of Patients with COVID-19 (IDSA) Where to get pemgarda (Pemgarda) EUA for the pre-exposure prophylaxis of COVID-19 (INVIYD) How well do you test: performance of the SARS-CoV-2 antigen rapid detection test (eBioMedicine) CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Infectious Disease Society guidelines for treatment and management (ID Society) Drug interaction checker (University of Liverpool) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) What to do when sick with a respiratory virus (CDC) When your healthcare provider is infected/exposed with SARS-CoV-2 (CDC) Managing healthcare staffing shortages (CDC) Steroids, dexamethasone at the right time (OFID) Anticoagulation guidelines (hematology.org) Remdesivir-associated survival outcomes among immunocompromised patients (CID) Remdesivir Effectiveness in Reducing the Risk of 30-day Readmission in Vulnerable Patients (CID) Measurement of circulating viral antigens post-SARS-CoV-2 infection (CMI: Clinical Microbiology and Infection) DUCI: driving under cognitive influence of COVID-19 (Neurology) Long COVID facts and findings: (LANCET: Regional Health Western Pacific) Letters read on TWiV 1158 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv

Le Dr. Xavier Cassard, chirurgien orthopédique et expert en ambulatoire depuis plus de 10 ans nous amène explorer la révolution de la chirurgie du genou en ambulatoire.Grâce à cette approche innovante, les patients peuvent désormais se faire poser une prothèse totale de genou le matin et rentrer chez eux le soir, une véritable prouesse médicale qui transforme l'expérience de la chirurgie.Le Dr. Cassard partage les avantages de cette approche : des patients plus mobiles, moins de complications post-opératoires, et une récupération plus rapide. Il explique également les défis auxquels il a été confronté lors de la mise en place de ce modèle, et comment la collaboration étroite avec les anesthésistes a joué un rôle clé dans son succès.Nous découvrons également l'importance d'une préparation minutieuse, d'une organisation fluide et de l'architecture des centres de soins, qui permettent de garantir des résultats optimaux. Au-delà des aspects techniques, ce modèle prône une relation humaine renforcée entre les soignants et les patients, avec un objectif partagé : créer une expérience positive, presque "waouh", malgré la nature invasive de la chirurgie.Cet épisode met en lumière l'évolution vers une médecine plus durable et efficiente, tant sur le plan médical qu'écologique, et montre comment la chirurgie ambulatoire pourrait bien être l'avenir des soins orthopédiques en France et ailleurs.-Notes et références de l'épisodePublications :Inpatient Versus Outpatient Surgery: A Comparison of Postoperative Mortality and Morbidity in Elective Operations https://pubmed.ncbi.nlm.nih.gov/36380104/Outpatient total knee arthroplasty: Readmission and complication rates on day 30 in 61 patients https://www.researchgate.net/profile/Jerome-Murgier/publication/327383902_Outpatient_Total_Knee_Arthroplasty_Re-Admission_and_Complication_Rates_on_Day_30_in_61_Patients/links/5b9c432892851ca9ed0aa196/Outpatient-Total-Knee-Arthroplasty-Re-Admission-and-Complication-Rates-on-Day-30-in-61-Patients.pdfIBiA, Maison de Chirurgie Ambulatoire. Plaidoyer pour une chirurgie ambulatoire autonome et responsable https://www.linkedin.com/pulse/ibia-maison-de-chirurgie-ambulatoire-plaidoyer-pour-une-cassard-mlh0e/?trackingId=t5yufYnoSnyWR4spVNYCWQ%3D%3DPersonnalités :Dr Jérôme Villeminot, HaguenauDr Thierry de Polignac, AnnecyDr Pascal Cariven, AlbiDr Mark K. Bowen, ChicagoBrian Oosteroff, Consultant Ambulatory Surgery, Suisse, https://brianoosterhoff.com/Dr Jérôme Murgier, BiarritzDr Dominique Claverie, anesthésiste, ToulouseEntreprises : Clinique des Cèdres, Toulouse : https://clinique-cedres-toulouse.ramsaysante.fr/Microport Orthopedics : https://www.microportortho.com/Ramsay Santé : https://www.ramsaysante.fr/Films « Sur le chemin de l'ambulatoire » - Disponibles sur Youtube :Alexandre Lunebourg, Michel Dottrens, Brian Oosterhoff, Centre DaisY des eHnv, SuisseBenoit Gignoux, Alexandre Vulliez, Clinique de la Sauvegarde, Capio, Lyon, FranceStephan Vehmeijer & Ilka Post, Orthoparc, Utrecht, NetherlandsMark Bowen, River North Same Day Surgical Center, Chicago , USAHenrik Husted , Billy Kristensen, Hvidovre Hospital, Copenhagen, Danemark / Version sous TitréeFrederic Picard, Golden Jubilee National Hospital, Glasgow , Scotland / STHenrik Husted , Billy Kristensen, Hvidovre Hospital, Copenhagen, DanemarkÉpilogue / Xavier Cassard / Version Fr / OASA 2018Episodes de Pharma minds :Pr Eric Vibert : https://podcast.ausha.co/pharma-minds/eric-vibert-puph-chir-transplant-hep-p-brousse-aphp-l-innovation-c-est-souvent-le-fruit-du-hasard

Georgina Energy PLC (LSE:GEX) CEO Anthony Hamilton takes Proactive's Stephen Gunnion through the company's latest operational update and its rapid progress following its admission to the main markets of the LSE. Hamilton explained that Georgina Energy listed on the 30th of July and released an operational update just days later. The update focuses on the development of the Hussar-1 well in Western Australia, with drilling operations set to commence in December. Key activities include commissioning a scoping study for capital and operating cost estimates, negotiating contract terms for gas separation, and ensuring reimbursement for development costs. Hamilton also discussed the process of obtaining drilling permits, which includes updating environmental impact studies and completing drilling plans for submission to DEMIRS (Department of Energy, Mines, Industry Regulation and Safety). Additionally, new seismic data and AMPTP surveys will help quantify the scale of the Hussar resource and identify any additional structures. At Mt Winter, progress is being made with indigenous land agreements, essential for obtaining the full exploration permit. Hamilton highlighted that the developments at Hussar will serve as a model for operations at Mt Winter, ensuring efficient replication of processes. Visit Proactive's YouTube channel for more videos, and don't forget to give the video a like, subscribe to the channel, and enable notifications for future content. #GeorginaEnergy #OperationalUpdate #HussarWell #WesternAustralia #AnthonyHamilton #EnergySector #LSE #GasExploration #SeismicData #EnvironmentalImpact #DrillingPlans #ProactiveInvestors #InvestmentUpdates #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

In Episode 442 of 'Relentless Health Value,' host Stacey Richter shares an intriguing outtake from a previous episode featuring Andreas Mang, senior managing director at Blackstone, discussing the critical issue of cost management in oncology side effect treatment. The conversation delves into the inefficiencies and patient harms caused by inadequate side effect management, particularly dehydration due to chemotherapy, and the resulting financial burdens on employers, taxpayers, and patients.  Stacey explores the importance of a value-based mindset in drug purchasing, integrating oncology care, and the potential financial and health benefits of better side effect management. She highlights various expert opinions and studies supporting these points, encouraging listeners to reconsider their approach to healthcare cost structures and patient care protocols. If you enjoy this podcast, be sure to subscribe to the free weekly newsletter to be a member of the Relentless Tribe.  01:12 Andreas Mang on oncology medication side effect management. 03:12 Mark Lewis, MD's Tweet. 03:39 Celena Latham's response. 04:22 How integrative oncology can save money and what it looks like. 04:47 EP157 with Ethan Basch, MD. 06:20 Why PBMs saving money doesn't necessarily mean savings for employers and payers. 07:36 EP435 with Dan Mendelson. 08:20 EP372 with Cora Opsahl. 08:40 EP331 with Al Lewis. 09:50 Stacey's second rumination. 10:19 Why having a value mindset when purchasing is a thing. 10:42 Stacey's third rumination. 12:03 EP370 with Erik Davis and Autumn Yongchu. 13:07 Why FFS does not pay or pay adequately for side effect management. 14:31 Stacey's final rumination. 17:08 Summarizing Stacey's four ruminations on this topic.

Patricia Vassallo, MD, Assistant Professor of Cardiology at Northwestern Medicine, highlights her research investigating the impact of socioeconomic status on readmission rates in patients undergoing acute type A aortic dissection repair.Dr. Vassallo, medical director of Code Aorta, discusses this program, which aims to provide expedited surgical care to patients with life-threatening aortic emergencies.

www.YourHealth.orgwww.SCHomeRx.comwww.thedisruptedpodcast.comwww.experiencinghealthcare.com www.YourHealth.Org

Dr. Ahzam Afzal, Co-Founder and CEO of Puzzle Healthcare, aims to reduce readmission rates to hospitals and skilled nursing facilities by focusing on discharge planning and post-acute care. High readmission rates can result in financial penalties and are often caused by the complexity of the patient's condition and social determinants of health. Puzzle is working with health systems and SNFs to implement a readmission prevention program that includes physiatry and care coordination 90 days after discharge.  Ahzam explains, "Hospital readmissions have become a focal point for our healthcare systems for several reasons. First and foremost, they are a key indicator of the quality of care being provided by these facilities. High readmission rates often suggest that patients may not be receiving the comprehensive care they need during their hospital stay or the necessary support post-discharge. This could be due to inadequate discharge planning, insufficient patient education on their conditions, or a lack of effective follow-up care."   "Additionally, readmissions place a substantial financial burden on healthcare facilities. Under the Affordable Care Act, hospitals with higher than expected readmission rates for certain conditions face significant penalties including reduced Medicare reimbursements. This policy was also extended to skilled nursing facilities through the Skilled Nursing Facility Value-Based Purchasing program, which penalizes SNF facilities based on their readmission rates starting in 2024."  #PuzzleHealthcare #ReadmissionPrevention #Hospitals #SkilledNursingFacilities #ValueBasedCare #PostAcuteCare #SDOH puzzlehealthcare.com Download the transcript here

Dr. Ahzam Afzal, Co-Founder and CEO of Puzzle Healthcare, aims to reduce readmission rates to hospitals and skilled nursing facilities by focusing on discharge planning and post-acute care. High readmission rates can result in financial penalties and are often caused by the complexity of the patient's condition and social determinants of health. Puzzle is working with health systems and SNFs to implement a readmission prevention program that includes physiatry and care coordination 90 days after discharge.  Ahzam explains, "Hospital readmissions have become a focal point for our healthcare systems for several reasons. First and foremost, they are a key indicator of the quality of care being provided by these facilities. High readmission rates often suggest that patients may not be receiving the comprehensive care they need during their hospital stay or the necessary support post-discharge. This could be due to inadequate discharge planning, insufficient patient education on their conditions, or a lack of effective follow-up care."   "Additionally, readmissions place a substantial financial burden on healthcare facilities. Under the Affordable Care Act, hospitals with higher than expected readmission rates for certain conditions face significant penalties including reduced Medicare reimbursements. This policy was also extended to skilled nursing facilities through the Skilled Nursing Facility Value-Based Purchasing program, which penalizes SNF facilities based on their readmission rates starting in 2024."  #PuzzleHealthcare #ReadmissionPrevention #Hospitals #SkilledNursingFacilities #ValueBasedCare #PostAcuteCare #SDOH puzzlehealthcare.com Listen to the podcast here

Commentary by Dr. Valentin Fuster

Commentary by Dr. Bobby Yeh and Dr. Aarti Asnani

What is the actual definition of the ICU readmission? Which are the rates and the main reasons behind readmissions of previously discharged patients? In this episode, our Host, Dr Yael Lichter, discuss challenging dogmas in ICU readmission with Ms. Jillian Hartin and Mr. John Welch, experts in the field. Join their discussion and learn more about the topic.

South African legend Mike Procter returns to the podcast for a candid conversation on all things Monkeygate, Kerry Packer and the South African readmission to cricket. He joins host Saqib Ali and resident podcast guest Vijay Arumugam. The conversation is a rich account on many phases of Procter's cricketing life where he was a player, coach, commentator and a match referee. Enough reading ....start listening please! https://www.amazon.com/Caught-Middle-Monkeygate-Politics-Autobiography/dp/1785312162 https://www.espncricinfo.com/cricketers/mike-procter-46793      

Matthew 15-15-20, 1 Corinthians 5- Confession Lord's Day 31-Theme- Church discipline is done out of love, in good order, for the honor of Christ and the salvation of the sinner.-1- The process for discipline- - Matthew 16- - Silent censure- - Public discipline- step 1- step 2- step 3- - Excommunication-2- The result of discipline- - The initial result- How to treat an excommunicated person- - The hoped for result- Readmission

Matthew 15-15-20, 1 Corinthians 5- Confession Lord's Day 31-Theme- Church discipline is done out of love, in good order, for the honor of Christ and the salvation of the sinner.-1- The process for discipline- - Matthew 16- - Silent censure- - Public discipline- step 1- step 2- step 3- - Excommunication-2- The result of discipline- - The initial result- How to treat an excommunicated person- - The hoped for result- Readmission

Matthew 15:15-20, 1 Corinthians 5: Confession Lord's Day 31Theme: Church discipline is done out of love, in good order, for the honor of Christ and the salvation of the sinner.1) The process for discipline - Matthew 16 - Silent censure - Public discipline step 1 step 2 step 3 - Excommunication2) The result of discipline - The initial result: How to treat an excommunicated person - The hoped for result: Readmission

Commentary by Dr. Candice Silversides

Episode 123 of Sport Unlocked, the podcast dissecting the week's sports news issues. On the agenda on October 1, 2023 with Rob Harris, Martyn Ziegler and Tariq Panja: Russia's readmission - UEFA splits European football; Osimhen abuse - why is it turned into transfer speculation?; English club's 17bn on social media claim; Marathon shoes; Running from drug testers Send any questions to the team on ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Twitter @SportUnlocked⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Check out videos from the interviews on Sport Unlocked's ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠YouTube channel⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠or ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Twitter⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ pages Music No Love by MusicbyAden ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://soundcloud.com/musicbyaden⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Creative Commons — Attribution-ShareAlike 3.0 Unported — CC BY-SA 3.0 Free Download / Stream: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://bit.ly/_no-love⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Music promoted by Audio Library ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://youtu.be/JgXz25Tw5d4⁠⁠⁠⁠⁠o⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Elizabeth's newborn baby was readmitted to hospital to treat jaundice which is one of the primary reasons a baby will need to return to hospital after discharge. She had to navigate conflicting medical advice and opinions on the ward which isn't an uncommon experience in the postpartum health space. I encourage you to listen to this episode because it really highlights the importance of breastfeeding education and having support people to advocate for you. Elizabeth will be back in a few weeks time to share her pregnancy journey and incredibly positive birth under the care of MGP midwives.See omnystudio.com/listener for privacy information.

Just taking a moment here to thank our Relentless Tribe for really getting yourselves involved in the work that I had originally kicked off to improve the outcomes for CKD (chronic kidney disease) patients in this country. With the momentum that we have so far, this Relentless Tribe of ours, we are really (for reals) going to produce measurable improvements for patients with CKD—so many of you, not just talking but actually out there, actively doing what you need to do so that patients do better, and it's making a difference. I have talked to doctors, other clinicians, administrators, IPAs, other provider organizations big and small, payers, societies, a great data company, a number of you who are consultants. It's crazy what we have been able to build so far, and we've been doing this for less than a year. The Relentless Tribe … let me tell you, we move mountains. We get patients properly diagnosed. We get them into appropriate treatment plans. What restores my faith in these rough times, we have encountered one PCP, one clinician after another; and the second that we show them the “as per the guidelines” way to accurately diagnose and stage chronic kidney disease (which is not just using eGFR for those clinicians who might be listening), yeah, that's it! These are great doctors, and they switch it up. They switch up what they are doing, and that makes my heart warm. These are doctors across the board, from ones in independent practices to ones maybe employed by academic medical centers. And once they have the right information, they use it. And it's a wonderful thing, and I cannot thank everybody who has contributed enough. We are making real differences in patients' lives. If what I am doing speaks to you in any way, please hit me up, because we're cooking with gas and I could not be prouder of this community of change agents that we have built here. You're amazing. You know what needs to be done, and you're not afraid to do it. Now, back to our regularly scheduled programming. In this healthcare podcast, I am talking with Secretary David Shulkin, MD, and Erin Mistry. Here's the first reason why I was interested in taking this interview after their public relations firm contacted me. We were at the thINc360 conference in DC earlier this summer, and I heard them talking about a new innovation to help patients on dialysis not die from infections, which … didn't realize how common that was and it seemed like a nice adjacency to our ongoing CKD work. I also thought this might be an opportunity to learn a little bit more about what's going on with hospital-acquired infections and infection control. Superbugs are hella scary, but one thing I'm just gonna point out—and, small sidebar here, but listen to the show with Bruce Rector, MD (EP300) for more on this—in recent times, I don't think there has been a pharma company who has managed to launch an antibiotic and achieve commercial success. So, what can easily wind up happening under the current payment model is that instead of just using the new antibiotic to treat resistant cases, there's this perverse incentive to push for the drug's use more broadly because more prescriptions, more money. But when the new antibiotic is used more broadly, that actually reduces its effectiveness against those resistant infections that it is here to treat. Okay … back to bloodstream infections now, which is the topic of the conversation today. If a patient has a central line infection and then gets sepsis, their chances of readmission within 30 days is almost 99%. This is not a little cohort. It's not small potatoes we're talking about here either. As Secretary Shulkin says during this interview that follows, if you're gonna make a preventative care economic case study, do it on hospital-acquired infections and, most particularly, those with central lines that lead to sepsis. Even with very short time horizons, you can make that case. So, that was two reasons for this interview. The third: I've been extremely intrigued by how and why decisions get made in hospitals for whether or not to buy and use potentially expensive new innovative things—specifically, innovative new things which are used during inpatient goings-on paid for with a DRG. DRG stands for Diagnostic Resource Group. Medicare (and others a lot of times) pays hospitals a flat sum to care for a patient coming in with heart failure or sepsis or needing dialysis, regardless of what services are actually delivered. There are something like 13,000 diagnoses and 5000 procedures that Medicare pays for with a DRG lump sum payment. It's up to the hospitals to make sure they buy low and sell high. So, you can see where this is going. A hospital can't go tell Medicare, “Hey, we just got some fancy new equipment or a better IV drug, so now we're gonna charge more.” The DRG is what the DRG is, and if the hospital chooses to spend more on the cost of goods, then the hospital makes less money. This is kind of along the same lines as Marty Makary, MD, MPH, talks about in his book Unaccountable. The purchasing department or some administrator somewhere is making decisions about what monitors to put in the ORs, and they pick the cheap ones that don't have the color contrast that the surgeons need to do a good job. But the monitors are cheaper, and the hospital can't pass on the costs. So, from a strictly purchasing perspective, it seems like fiscally solid purchasing, even if doctors are not on board with the decisions and patients have worse outcomes. Seems like somebody over at CMS figured this out, and to solve for the “purchasers or administrators or whomever who are not willing to lose money by using new stuff,” Medicare introduced this extra payment opportunity, which we'll get into in the interview today. But the short version is this: Biotech companies, device companies, others who are innovators can apply to get Medicare to pay a so-called NTAP to healthcare delivery organizations who use the new product. NTAP stands for new technology add-on payment. Again, these are additional Medicare payments in the inpatient setting that may be available to those who use certain qualifying new technologies as part of services rendered that are normally part of a DRG. Here's my assessment of the tension between hospitals and plan sponsors because, yeah, when hospitals get paid more for something, that is coming out of somebody's wallet. If we assume that we're talking about an innovation that actually produces better patient outcomes, I don't know how anyone can say there's a right answer here. If the innovation is expensive, you're gonna have payers worried about the money, and fair enough. I can easily hear them saying something like, “We're already paying however much to the hospital, and now there's an additional charge that's allowed on top of the DRG?” On the other hand, if I'm a patient, yeah, it would kinda suck to not get the innovation that's gonna save my life or whatever because the payers insist on paying no more than the DRG and the hospital won't pay out of their own pocket. Really enjoyed my conversation today with Secretary David Schulkin. Secretary Shulkin spent his career running healthcare systems, mostly in the Northeast. A number of years ago, he entered the Obama administration to run the VA (Veterans Affairs) healthcare system. In the Trump administration, Dr. Shulkin was in the Cabinet as the Secretary of the Department of Veterans Affairs. Secretary Shulkin now has a consulting firm and is working with CorMedix. Erin Mistry, my second guest today, spent her career in health systems and then in biopharma. She now works for CorMedix. My sincere thanks for helping validate a couple of facts in this intro to Scott Haas, Autumn Yongchu, and Erik Davis from USI. For more on the topic of hospitals getting paid to administer drugs through a patient's medical benefit, listen to the show with Autumn Yongchu and Erik Davis (EP370). They cover the ways hospitals sometimes can figure out how to charge plan sponsors and patients 6x the cost of the drug. Acronym alert! CVC, which comes up a couple of times in the interview that follows, stands for central venous catheter, which is something that many dialysis patients have. Second Acronym Alert! QIDP stands for Qualified Infectious Disease Product. A QIDP qualifies for a special NTAP incentive specifically for infectious disease products. So again, just recapping what an NTAP is. It's a new technology add-on payment, and it's paid for by CMS, who has studied the new technology thing and determined that they actually want hospitals to be using it. So, they're willing to pay more than the DRG if a hospital uses this thing, because they recognize if they don't pay more, then the hospital won't eat the cost. And just because of all the focus on infectious disease right now, these qualified infectious disease products have some prioritized status over at CMS relative to getting the NTAP designation.   You can learn more by connecting with Secretary Shulkin, Erin, and CorMedix on LinkedIn.     Honorable David J. Shulkin, MD, was the ninth Secretary of the US Department of Veterans Affairs (VA), having been appointed by President Trump. Secretary Shulkin previously served as Under Secretary for Health, having been appointed by President Obama and confirmed twice unanimously by the US Senate. As Secretary, Dr. Shulkin represented the 21 million American veterans and was responsible for the nation's largest integrated healthcare system, with over 1200 sites of care serving over 9 million veterans. Prior to coming to VA, Secretary Shulkin was a widely respected healthcare executive, having served as chief executive of leading hospitals and health systems, including Beth Israel in New York City and Morristown Medical Center in northern New Jersey. As an entrepreneur, Secretary Shulkin founded and served as the chairman and CEO of DoctorQuality and has served on boards of managed care companies, technology companies, and healthcare organizations. Since leaving government, Secretary Shulkin has been the University of Pennsylvania Leonard Davis Institute Distinguished Health Policy Fellow and Professor at the Jefferson University College of Population Health. He is a board-certified internist and received advanced training in outcomes research and economics as a Robert Wood Johnson Foundation Clinical Scholar at the University of Pennsylvania. Over his career, Secretary Shulkin has been named one of the “100 Most Influential People in American Healthcare” by Modern Healthcare.   Erin Mistry is executive vice president and chief commercial officer of CorMedix, appointed in January 2023. She served as senior vice president of payer strategy, government affairs, and trade from 2020 to 2022. She leads the company's commercial strategy and execution. Erin brings over 15 years of industry experience at the executive level, from consulting to in-house executive management. Prior to joining CorMedix, Erin was vice president of market access at Intarcia Therapeutics, responsible for pricing, coverage, access, real-world evidence (RWE), and channel strategy for a competitive product in type 2 diabetes. Erin was also senior managing director at Syneos Health, where she was responsible for the global P&L of the Value Access Practice. In this capacity, Erin consulted on commercial strategy and market access with emerging, mid, and large biopharma across a broad range of therapeutic categories. Erin holds an undergraduate and master degree in biomechanical engineering from North Carolina State University.   10:17 What is happening with antimicrobial stewardship and combatting antibiotic resistance? 11:22 How is CorMedix working to prevent infections caused by catheters, and who is paying for the innovation to prevent this type of infection? 12:38 Why should hospitals pay for new innovations like the one created by CorMedix? 14:32 What do hospitals need to do in order to realize the benefit of this new innovation? 16:14 What does antimicrobial stewardship mean to Secretary Shulkin? 17:06 “If we continue to ignore this and not use antibiotics appropriately, it's simply a matter of time before the superbugs figure out how to take over.” —Secretary Shulkin 18:32 “Anytime you have a preventative medicine, you have to have an economic story.” —Erin 20:55 Who is using this product, and who is paying for it? 21:38 What needs to be considered if rolling out an innovation like this broadly? 24:47 How does an innovative product qualify for an NTAP? 26:37 “It's not just financial economics; it's mortality data.” —Erin 28:08 What does Secretary Shulkin see as “shifting the paradigm”?   You can learn more by connecting with Secretary Shulkin, Erin, and CorMedix on LinkedIn.   @DavidShulkin and Erin Mistry of @CorMedix_News discuss payment for #innovation in #hospital procedures and #DRG on our #healthcarepodcast. #healthcare #podcast #digitalhealth #hcmkg #healthcarepricing #pricetransparency #healthcarefinance   Recent past interviews: Click a guest's name for their latest RHV episode! Keith Passwater and JR Clark (Summer Shorts 7), Lauren Vela (Summer Shorts 6), Dr Jacob Asher (Summer Shorts 5), Eric Gallagher (Summer Shorts 4), Dan Serrano, Larry Bauer, Dr Vivek Garg (Summer Shorts 3), Dr Scott Conard (Summer Shorts 2), Brennan Bilberry (Summer Shorts 1), Stacey Richter (INBW38)

Have you ever struggled choosing which type of stoma to mature in an anatomically or medically challenging patient? What about wrestled with the associated postoperative complications? Join Drs. Galandiuk, Bolshinsky, Kavalukas, and Simon as they discuss ostomy creation and management of stoma complications. Hosts: - Susan Galandiuk MD, University of Louisville, Louisville, Kentucky, @DCREdInChief - Vladimir Bolshinsky MD, Peninsula Health, Victoria, Australia, @bolshinskyv - Sandy Kavalukas MD, University of Louisville, Louisville, Kentucky, @sandykava - Hillary Simon DO, University of Louisville, Louisville, Kentucky, @HillaryLSimon Producer: - Manasa Sunkara MS3, University of Louisville, Louisville, Kentucky, @manasasunkara12 Learning objectives:  - Review pre-operative stoma marking and ostomy education.  - Understand “bail-out” ostomy creation options in medically and anatomically challenging patients.  - Discuss common postoperative ostomy complications and management. - Review common peristomal skin pathology and treatment options.  Video References: - Colwell, Janice C. A.P.R.N., C.W.O.C.N.1; Williams, Toyia M.S.N., R.N.2. Management of the Patient With a Prolapsed Ileostomy. Diseases of the Colon & Rectum 65(12):p e1073, December 2022. | DOI: 10.1097/DCR.0000000000002605 https://www.youtube.com/watch?v=Wx83CpRLkqk  Non-operative management of stoma prolapse/reduction   - Colwell, Janice C. A.P.R.N.. Management of the Patient With a Retracted Loop Ileostomy Located in a Crease. Diseases of the Colon & Rectum 65(3):p e182-e183, March 2022. | DOI: 10.1097/DCR.0000000000002367 https://www.youtube.com/watch?v=mc6o7nG1fsQ  Management of a retracted stoma, in a crease, with peristomal skin breakdown - Watanabe, Kazuhiro M.D., Ph.D.; Kohyama, Atsushi M.D., Ph.D.; Suzuki, Hideyuki M.D., Ph.D.; Kajiwara, Taiki M.D., Ph.D.; Karasawa, Hideaki M.D., Ph.D.; Ohnuma, Shinobu M.D., Ph.D.; Kamei, Takashi M.D., Ph.D.; Unno, Michiaki M.D., Ph.D.. Slug Method: A Technique for Stoma Prolapse Reduction Using High Osmolality of the 50% Glucose Solution. Diseases of the Colon & Rectum 63(12):p e565, December 2020. | DOI: 10.1097/DCR.0000000000001798  https://cdn-links.lww.com/permalink/dcr/b/dcr_1_1_2020_09_01_watanabe_20-00282_sdc1.mp4  Osmotic reduction Other References: - Baker ML, Williams RN, Nightingale J.. Causes and management of a high-output stoma. Colorectal Dis. 2011;13(2):191–197. doi: 10.1111/j.1463-1318.2009.02107.x. - Behrenbruch, C., Carr, G., Johnston, M. and Woods, R. (2019), Three-point stapled fixation technique to manage ileostomy spout retraction. ANZ Journal of Surgery, 89: 423-424. doi: 10.1111/ans.15006 - O'Brien, Stephen J. M.B. B.Ch., B.A.O.; Ellis, C. Tyler M.D., M.S.C.R.. The Management of Peristomal Pyoderma Gangrenosum in IBD. Diseases of the Colon & Rectum 63(7):p 881-884, July 2020. | DOI: 10.1097/DCR.0000000000001701 - Paquette IM, Solan P, Rafferty JF, Ferguson MA, Davis BR.. Readmission for dehydration or renal failure after ileostomy creation. Dis Colon Rectum. 2013;56(8):974–979. doi: 10.1097/DCR.0b013e31828d02ba - Steele S, Hull Tracy, Hyman N, Maykel J, Read T, and Whitlow C. The ASCRS Textbook of Colon and Rectal Surgery. 4th Edition. Volume II. Springer, Switzerland AG, 2022. Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out other recent Colorectal Surgery Episodes here: https://behindtheknife.org/podcast-category/colorectal/

On this episode of WOCTalk, we sit down with Jill Cox, PhD, RN, APN-C, CWOCN, FAAN and Rachele Durango, MSN, RN, APN-C, CWOCN, two of the authors of the article titled, “Predictors of Hospital Readmission in Patients Undergoing Creation of an Intestinal Ostomy” published in the May/June 2023 issue of the Journal of Wound, Ostomy, and Continence Nursing (JWOCN®), the official journal of the WOCN® Society.The purpose of this study was to identify predictors of 30- and 60-day hospital readmission in patients undergoing ileostomy or colostomy creation.To learn more about the Journal of Wound, Ostomy, and Continence Nursing (JWOCN), the official journal of the WOCN Society, click here. Episode Resources:Click here to read the JWOCN article titled, Predictors of Hospital Readmission in Patients Undergoing Creation of an Intestinal Ostomy About the Speakers:Jill Cox, PhD, RN, APN-C, CWOCN, FAAN, has as been a WOC nurse for 30 years in the acute care setting, caring for patients with all types of wounds and ostomies. In addition, she has presented educational programs focused on the care of patients with ostomies, and wounds and have conducted primary clinical research on these topics. Jill have spoken nationally and regionally on topics related to WOC practice. Rachele Durango, MSN, RN, APN-C, CWOCN, graduated from Ramapo College of NJ with a Bachelor's of Science in Nursing in 2010 and began working as a Registered Nurse at a suburban teaching hospital in Northern NJ. Rachele, graduated from William Paterson University of NJ with a Master's of Science in Nursing in 2017 and became certified as an Adult Gerontology Primary Care Nurse Practitioner. After graduation, went on to specialize in wound, ostomy, and continence care, completing the WEB WOC Program and became a Certified Wound, Ostomy, and Continence Nurse in 2018. Rachele currently work full-time at a suburban teaching hospital in Northern NJ as a Certified Wound, Ostomy, and Continence Nurse Practitioner.

Stephanie Taylor, MD, Associate Professor of Internal Medicine at Carolinas Medical Center presents at Critical Care Grand Rounds, a lecture entitled, "Clinical Subtypes of Sepsis Survivors Predicts Readmission and Mortality After Hospital Discharge.”

In this episode, Patrick W. G. Mallon, MB, BCh, PhD, FRACP, FRCPI, discusses new data on COVID-19 presented at ECCMID 2023, including:Treatment in special populationsREDPINE: remdesivir in people with renal impairment hospitalized for COVID-19 pneumoniaRemdesivir and readmission for COVID-19 in immunocompromised patientsMolnupiravir vs nirmatrelvir plus ritonavir for COVID-19 with hematologic malignancyManagement of patients with severe diseaseRECOVERY: higher-dose vs standard-dose corticosteroids for hospitalized patients with COVID-19Real-world study of tocilizumab vs baricitinib for severe COVID-19Novel antiviralsEnsitrelvirBemnifosbuvir Novel vaccinesNB2155AZD2816/AZD1222qNIV/CoV2373GRT-R910NVX-CoV2373 in people with HIVFaculty:  Patrick W. G. Mallon, MB, BCh, PhD, FRACP, FRCPIProfessor of Microbial DiseasesCentre for Experimental Pathogen Host ResearchUniversity College DublinDublin, IrelandContent based on an online CME/CE program supported by independent educational grants from Gilead Sciences, Inc. and Novavax.  Link to full program: bit.ly/3niXGJ6Link to downloadable slides: bit.ly/3LUFejG

Commentary by Dr. Candice Silversides

On this special end-of-year crossover episode, the hosts from Up Next in Commerce, Marketing Trends, and IT Visionaries meet up again to discuss their biggest takeaways from their guests over the past year, and to make some predictions for what should be an exciting 2023 in marketing, tech, and e-commerce.Tune in to learn:Why your employees are your greatest customers (8:41)Why good business instincts can help overcome a lack of data  (14:28)Why intuition matters, even in data-driven industries (20:53)Client ad readMission.org is a media studio producing content for world-class clients. Learn more at *LINK*.Mentions:David Ting, ZenniDavid Heinemeier Hansson, 37signalsStephanie Dobbs Brown, CMO, Intercontinental ExchangeLil' WayneKevin Warren, UPSEric Toda, MetaClient ad readMission.org is a media studio producing content for world-class clients. Learn more at *LINK*.

HRRP stands for Hospital Readmissions Reduction Program, by the way. I wanted to encore this episode with Dr. Rishi Wadhera because it's a great representation of a common root cause reason why quality metrics sometimes don't end well in real life. This root cause is otherwise known as Goodhart's Law, and we dig into Goodhart's law later on in this healthcare podcast. But the actual and ultimate impact of HRRP is also a pretty good representation of the consequences, what happens, when you create a blunt-force policy that assumes hospitals with very different circumstances are the same. Before we kick in to the episode, I asked Dr. Wadhera, my guest today as aforementioned, if there'd been any updates regarding HRRP since this show originally aired last year; and he told me that two key pieces have come out this past month in JAMA journals calling out CMS (Centers for Medicare & Medicaid Services) to move on from/retire this policy: A Decade of Observing the Hospital Readmission Reductions Program—Time to Retire an Ineffective Policy Readmission Reduction as a Hospital Quality Measure: Time to Move on to More Pressing Concerns? Thanks so much to Dr. Steve Schutzer and also BoneDoc66 for your really nice reviews this past month. So appreciated … thank you so much! And here is your encore. Today's guest is Rishi Wadhera, MD, MPP. Dr. Wadhera authored a retrospective analysis in the BMJ about the HRRP, which we will talk about in this healthcare podcast. Dr. Wadhera is a cardiologist at Beth Israel Deaconess Medical Center. He also has a master's in public policy at the Harvard Kennedy School of Government and also a master's in public health from the University of Cambridge. But here's the larger epiphany that pertains to all value-based care and all quality metrics which Dr. Wadhera brings up in this healthcare podcast and which my nerd heart could not love more: Goodhart's Law. This law is the root of so very many problems. Goodhart's Law is this (which I learned from Dr. Wadhera): “When a measure becomes a target, it ceases to be a good measure.” In other words, when we set a goal, people will try to take a shortcut to the goal, regardless of the consequences. And sometimes the consequences, paradoxically, are to do worse at the goal. Maybe because bean counters and admins and maybe even goal-oriented clinicians themselves will go right to the end goal, inadvertently skipping a whole bunch of (it turns out) rate-critical steps. For example, teaching to the test may not lead to students who deeply understand a subject. And anyone trying to achieve value-based care success, improve quality, form collaborations, or make sales might want to remember that old proverb, “Sometimes the shortest way home is the long way around.”   You can learn more at Dr. Wadhera's Harvard Catalyst profile and the Beth Israel Deaconess Medical Center Web site.   Rishi K. Wadhera, MD, MPP, MPhil, is an assistant professor of medicine at Harvard Medical School, a cardiologist at Beth Israel Deaconess Medical Center (BIDMC), and the associate program director of the cardiovascular medicine fellowship at BIDMC. He is also health policy and equity researcher at the Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology. Dr. Wadhera received his MD from the Mayo Clinic School of Medicine as well as an MPhil in public health as a Gates Cambridge Scholar from the University of Cambridge. He completed his internal medicine residency and cardiovascular medicine fellowship at Brigham and Women's Hospital in Boston. During this time, he also received a master's in public policy (MPP) at the Harvard Kennedy School of Government, with a focus on health policy. Dr. Wadhera's research spans questions related to healthcare access, quality, and disparities, as well as understanding how local, state, and national policy initiatives impact care delivery, health equity, and outcomes. Dr. Wadhera has published more than 80 articles to date, and he receives research support from the National Heart, Lung, and Blood Institute (NHLBI) and the National Institutes of Health (NIH)   03:30 What was the Hospital Readmissions Reduction Program intended to do? 05:22 Why did the Centers for Medicare & Medicaid (CMS) think some readmissions were preventable? 06:02 “The spirit of the Hospital Readmissions Reduction Program was to incentivize hospitals to improve … discharge planning, transitions of care, and post-discharge follow-up and care.” 06:58 How has research in the last few years changed the thoughts on the effectiveness of the Hospital Readmissions Reduction Program? 08:16 “The 30-day readmission measure—it's an incomplete measure.” 11:48 “I think patients … are smart, and they know what's going on.” 13:34 “What's happening is, we're just increasing the number of times they need to come back to the ER within that 30-day period.” 13:55 “The weird thing about the HRRP is that when it evaluates hospitals' 30-day readmission rates, it's a yes-no phenomenon.” 15:03 “What CMS does is, it risk adjusts … and that is what we should be doing.” 18:30 “This program has been incredibly regressive.” 19:04 “Poverty, neighborhood disadvantage, housing instability—these factors are out of hospitals' control.” 21:50 “Blunt policies like this that are rolled out nationally probably elicit mixed behavioral responses.” 22:06 “It just makes no sense to take resources away from hospitals.” 22:32 EP295 with Rebecca Etz, PhD. 23:47 What's the way to improve quality of care globally? 25:37 “CMS's approach to improving quality of care has really anchored … [that] to payment.” 26:08 “It's time for us to rethink what our approach to quality improvement should be.” 29:22 “Policy makers have an obligation to rigorously test the impact of these types of policies before they roll them out nationally.” 31:41 Can you scale healthcare nationally?   You can learn more at Dr. Wadhera's Harvard Catalyst profile and the Beth Israel Deaconess Medical Center Web site.   @rkwadhera of @BIDMChealth discusses #HRRP on our #healthcarepodcast. #healthcare #podcast #digitalhealth #vbc #hospitalreadmission What was the Hospital Readmissions Reduction Program intended to do? @rkwadhera of @BIDMChealth discusses #HRRP on our #healthcarepodcast. #healthcare #podcast #digitalhealth #vbc #hospitalreadmission Why did CMS think some readmissions were preventable? @rkwadhera of @BIDMChealth discusses #HRRP on our #healthcarepodcast. #healthcare #podcast #digitalhealth #vbc #hospitalreadmission “The spirit of the Hospital Readmissions Reduction Program was to incentivize hospitals to improve … discharge planning, transitions of care, and post-discharge follow-up and care.” @rkwadhera of @BIDMChealth discusses #HRRP on our #healthcarepodcast. #healthcare #podcast #digitalhealth #vbc #hospitalreadmission How has research in the last few years changed the thoughts on the effectiveness of the Hospital Readmissions Reduction Program? @rkwadhera of @BIDMChealth discusses #HRRP on our #healthcarepodcast. #healthcare #podcast #digitalhealth #vbc #hospitalreadmission “The 30-day readmission measure—it's an incomplete measure.” @rkwadhera of @BIDMChealth discusses #HRRP on our #healthcarepodcast. #healthcare #podcast #digitalhealth #vbc #hospitalreadmission “What CMS does is, it risk adjusts … and that is what we should be doing.” @rkwadhera of @BIDMChealth discusses #HRRP on our #healthcarepodcast. #healthcare #podcast #digitalhealth #vbc #hospitalreadmission “Blunt policies like this that are rolled out nationally probably elicit mixed behavioral responses.” @rkwadhera of @BIDMChealth discusses #HRRP on our #healthcarepodcast. #healthcare #podcast #digitalhealth #vbc #hospitalreadmission “It just makes no sense to take resources away from hospitals.” @rkwadhera of @BIDMChealth discusses #HRRP on our #healthcarepodcast. #healthcare #podcast #digitalhealth #vbc #hospitalreadmission What's the way to improve quality of care globally? @rkwadhera of @BIDMChealth discusses #HRRP on our #healthcarepodcast. #healthcare #podcast #digitalhealth #vbc #hospitalreadmission “It's time for us to rethink what our approach to quality improvement should be.” @rkwadhera of @BIDMChealth discusses #HRRP on our #healthcarepodcast. #healthcare #podcast #digitalhealth #vbc #hospitalreadmission Can you scale healthcare nationally? @rkwadhera of @BIDMChealth discusses #HRRP on our #healthcarepodcast. #healthcare #podcast #digitalhealth #vbc #hospitalreadmission   Recent past interviews: Click a guest's name for their latest RHV episode! Ge Bai (Encore! EP356), Dave Dierk and Stacey Richter (INBW37), Merrill Goozner, Betsy Seals (EP387), Stacey Richter (INBW36), Dr Eric Bricker (Encore! EP351), Al Lewis, Dan Mendelson, Wendell Potter, Nick Stefanizzi, Brian Klepper (Encore! EP335), Dr Aaron Mitchell (EP382), Karen Root, Mark Miller, AJ Loiacono, Josh LaRosa, Stacey Richter (INBW35), Rebecca Etz (Encore! EP295), Olivia Webb (Encore! EP337), Mike Baldzicki, Lisa Bari, Betsy Seals (EP375), Dave Chase, Cora Opsahl (EP373), Cora Opsahl (EP372), Dr Mark Fendrick (Encore! EP308), Erik Davis and Autumn Yongchu (EP371), Erik Davis and Autumn Yongchu (EP370)

In this session recorded at DPHARM 2022, Memorial Sloan Kettering Cancer Center shares about their Connected Care protocol. Digital monitoring of patients has the potential to better the delivery of cancer care through improved patient-provider communication, enhanced symptom and toxicity assessment and management, and optimized engagement across the cancer continuum. Remote monitoring is especially crucial when patients are at high risk for experiencing symptoms or toxicities from treatment. During these episodes, patients and clinicians benefit from routine assessments of electronic patient-reported outcomes (ePROs) to identify symptoms early and prevent adverse outcomes. The Connected Care protocol provides remote monitoring to medical oncology patients for 10-days post hospital discharge as this is a high-risk period for patients due to a lingering symptom burden and a need for enhanced patient-clinician communication as symptom management shifts from the inpatient to outpatient team. Specifically, Dr. Daly will discuss: The feasibility and acceptability of remote monitoring in the post discharge setting for patients with cancerPatient perspectives for remote monitoring post hospital dischargeePRO versus device and challenges with implementationThoughts on the right data to collect and at what intervals Speaker: Robert Daly, MD, MBA, Assistant Attending Medical Oncologist, Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center

“We like to consider ourselves the Waze of surgery,” says Todd Usen, CEO of ActivSurgical. Waze gathers and presents data from the road in real time, so that driver's can navigate their trip successfully and avoid problems before they occur. Similarly, ActivSurgical uses sensors and AI to anticipate problems that aren't visible to a surgeon's naked eye, and complements where a human is limited. This real time data is available not only to the surgeon performing surgery, but to surgeons, live throughout the world.  With everyone having access to the same information, patients entering surgery can rest assured that they can receive a standardized level of care regardless of a surgeon's experience. This also has the potential to decrease time spent in hospital, and lowers the rate of readmission.  Readmission not only increases risk of secondary problems and even death, but has implications on health insurance rates.  Quotes: “Why does the 17 year old driver get all this amazing information that a 50 year old driver gets, whether it's a rear view camera, whether it's an orange light in their side view mirror to tell you that there's a car in your blind spot, a seat that vibrates if you switch lanes. Yet, you go to surgery and a surgeon just out of fellowship doesn't get the same information that a surgeon that's been practicing for 30 years does. It's all intuition and skills. What we're trying to do is bring that information live to the screen. So every patient around the world should have the confidence that their surgeon has the same exact information as other surgeons to get a great outcome.” (3:27-4:03 | Todd)  “The world's not going to be hardware forever.” (8:34-8:36 | Todd) “If you're a football fan, and you ever watched the NFL on TV, you know, there's that first down marker that that we see on the screen, that yellow line, but the players don't see that we see it on TV, I want the players to see that yellow line, I want the doctors to see that yellow line live.” (32:38-32:52 | Todd)  Connect with Brendan Dell: LinkedIn: https://www.linkedin.com/in/brendandell/ YouTube: https://www.youtube.com/c/BrendanDell Instagram: @thebrendandellTikTok: @brendandell39 Buy a copy of Brendan's Book, The 12 Immutable Laws of High-Impact Messaging: https://www.indiebound.org/book/9780578210926    Connect with Todd Usen: activsurgical.comCheck out Todd Usen's recommended books: The Boys in the Boat: Nine Americans and Their Epic Quest for Gold at the 1936 Berlin Olympics by Daniel James Brown https://www.indiebound.org/book/9780143136965   Build: An Unorthodox Guide to Making Things Worth Making by Tony Fadell https://www.indiebound.org/book/9780063046061   Rogue Warrior by Richard Marcinko  https://www.indiebound.org/book/9780671795931 Please don't forget to rate, comment, and subscribe to Billion Dollar Tech on Apple, Spotify, or wherever you listen to podcasts! Use code Brendan30 for 30% off your annual membership with RiverSide.fm    Podcast production and show notes provided by HiveCast.fm

In this episode, Princy N. Kumar, MD, and Paul E. Sax, MD, discuss new COVID-19 data from IDWeek 2022, including:COVID-19 vaccines, including omicron BA.1 bivalent boosterRisk factors for breakthrough COVID-19 infectionsCOVID-19 diagnostics, including digital droplet PCRCOVID-19 therapeutics, including:Nirmatrelvir plus ritonavirTixagevimab plus cilgavimabBaricitinibTocilizumabInhaled interferon β-1aCOVID-19 therapeutics and outcomes in patients with immunocompromiseLong COVIDPresenters:Princy N. Kumar, MD, FIDSA, MACPProfessor of Medicine and MicrobiologyChief, Division of Infectious Diseases and Travel MedicineSenior Associate Dean of StudentsGeorgetown University School of MedicineWashington, DCPaul E. Sax, MDClinical DirectorHIV Program and Division of Infectious DiseasesBrigham and Women's HospitalProfessor of MedicineHarvard Medical SchoolBoston, MassachusettsFollow along with the downloadable slideset at:http://bit.ly/3gkJI67Link to full program:http://bit.ly/3TSVthM

A Commonwealth team led by Assistant Secretary-General Prof Luis Franceschi has begun a series of meetings in Zimbabwe to assess its readiness to be readmitted into the 56-member group. Foreign Affairs Minister Frederick Shava says the country was determined to rejoin the group. The delegation will assess the progress made in several areas, including judicial independence, electoral reforms, and the protection of human rights including the freedom of association and media freedoms. Harare believes it has complied with the conditions. Prof Francheschi says that Zimbabwe's readmission was not a political issue and should not be treated as such.

Harry McGee, political correspondent, discusses the potential return of former Fianna Fáil leader and taoiseach Bertie Ahern.

As always, feel free to send us questions, comments or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through instagram or twitter, @nicupodcast. Or contact Ben and Daphna directly via their twitter profiles: @drnicu and @doctordaphnamd. Papers discussed in today's episode are listed and timestamped below.enjoy!________________________________________________________________________________________Show notes and articles can be found on our website: www.nicupodcast.com/058-journal-club/This podcast is proudly sponsored by Chiesi and by Reckitt/Mead-Johnson

Dr. Barbara Decker discusses maternal obstetric complications and non-elective postpartum readmissions in women with prior stroke, migraine, multiple sclerosis, and myasthenia gravis. Show references: https://n.neurology.org/content/early/2022/02/15/WNL.0000000000200007  

Dr. Tesha Monteith talks with Dr. Barbara Decker about maternal obstetric complications and non-elective postpartum readmissions in women with prior stroke, migraine, multiple sclerosis, and myasthenia gravis. Read the full article in Neurology.

Tune in to learn:How They Were Able to Shift to an Online Only Company (00:00)About Eolab (06:00)Edward's Journey into His Current Role (19:25)How they get customers to adopt their products. (23:58)Mentions:EcolabClient ad readMission.org is a media studio producing content for world-class clients. Learn more at *LINK*.

What is it that brought you into marketing? For Steven Bushong, he started in product design and loved receiving the feedback from customers to help improve his product. Eventually he moved to one of the biggest companies in the world, Disney, where he continued that passion of direct consumer feedback - which took him to the world of marketing where he stayed for decades. Listen to this episode to hear about what he's learned working with these massive companies, and how he currently helps businesses improve their teams to create successful products and campaigns. Tune in to learn:Where Steven Started His Career (00:00)His Transition to Disney (5:29)Steven's Message to Marketing Leaders (10:31)Steven's Ideal Customer (17:17)How to Improve Marketing Internally (23:32)His Thoughts on the Metaverse (26:45)Salesforce Lighting Round (34:47)Client ad readMission.org is a media studio producing content for world-class clients. Learn more at *LINK*.

Hospital Readmissions Guru and Healthcare Futurist Dr. Josh Luke takes a look back over the past 10 years to share what strategies have worked with readmission prevention. Josh also shares about how he became known as a expert in the readmission and care transitions space through his development of the National Readmission Prevention Collaborative, which took off in the early days of the readmission penalties.

Believe me, filling in for the uncontested master of podcasts, Stacey Richter, is just a tad unnerving! My name is Dr. Steve Schutzer. I'm an orthopedic surgeon specializing in joint replacement surgery, and I think it's fair to say that I'm more comfortable, in my own lane, doing complex surgery than doing this introduction to our encore podcast 294 entitled “Building a Center of Excellence: A Playbook for Physician Entrepreneurs,” which aired originally in October 2020. But when Stacey graciously offered me the honor of doing so, I said to myself (sic: Steve, suck it up) what an opportunity to share with the devoted listeners of this show my humble perspectives on the prominent position COEs (also known as Centers of Excellence) are playing in this rapidly accelerating, evolving, and exciting healthcare landscape. So, there's an ancient Chinese proverb that goes like this: “When the wind of change blows, some build walls, and others build windmills”—or in this case, Centers of Excellence! And the winds of change in healthcare are blowing, maybe even reaching gale force. In the year since episode 294 aired, there's been unambiguous upsurge of activity, in part fueled by the pandemic, that has collectively and finally moved the healthcare value agenda across the chasm, over the inflection point—and there's no turning back. Unaccountable fee for service as the predominant payment model for healthcare services is, well, shall we say, on its last legs—being replaced by reimbursement models that are aligned with the clinical and financial outcome of the services actually delivered to our patients. For COEs, that's characteristically in the form of predictable bundled payments and fully warrantied episodes of care. Question: Where do COEs fit in this new landscape? Answer: COEs are the common pathway for all healthcare purchasers (whether they're self-funded employers, advanced primary care groups, Medicare Advantage—all of them) to steer agnostically to high-quality specialists focused on a defined set of healthcare services and who are willing to assume total cost of care for their product. And the favorable impact of COEs on the ROI for purchasers has now moved beyond the realm of theory to indisputable. Take, for example, the recent report by the RAND Corporation published earlier this year in Health Affairs: A study of over 2300 patients who had either total joint, spine, or bariatric surgery done under the Carrum Health program at one of their COEs. Carrum Health is a value-based national COE platform that connects self-insured employers with top providers under standardized bundled payment arrangements. And now in full disclosure, I serve as medical advisor for the company; and our program, the Connecticut Joint Replacement Institute in Hartford, Connecticut, is actually a Carrum COE. But in this independent RAND analysis of two years of medical claims data, the savings per procedure when the surgery was done at a Carrum COE was over $16,000 per procedure. Readmission rates were reduced 80% on average. Out-of-pocket cost to the patient? Zero. And an astonishing 30% of patients who were in the queue awaiting surgery ultimately were treated nonoperatively! Peter Hayes is president and CEO of the Healthcare Purchaser Alliance of Maine and a frequent guest on this podcast. His organization has been under contract with Carrum for approximately two years and recently reported an ROI of 58% and plan savings approaching $1 million. And these data also closely reflect that reported in the Harvard Business Review two years ago by Ruth Coleman and colleagues from their experience with Walmart COEs. Finally, you know, I heard Stacey say of COEs in one of her podcasts, “This is not something you can do on a Tuesday.” Agree. Prescient advice. As you will hear once again in just a moment, this takes work. But physician leaders and entrepreneurs, take heed. Although you won't be able to stand this up on a Tuesday, there's no reason why you can't begin next Monday. You can contact Dr. Schutzer at steve.schutzer@gmail.com and learn more at the Novel Healthcare Solutions website.   Steven F. Schutzer, MD, graduated with honors from Union College and the University of Virginia School of Medicine. Following a surgical internship at the University of Rochester, he served as lieutenant in the Medical Corps of the United States Navy. After his tour of duty, Dr. Schutzer did his general surgical training at the University of Rochester and then completed his orthopedic residency at the University of Connecticut. He was then a fellow in adult hip and reconstructive surgery at the Massachusetts General Hospital, after which he entered practice in Hartford, Connecticut. Dr. Schutzer is a founding member and medical director of the Connecticut Joint Replacement Institute (CJRI), a Center of Excellence at Saint Francis Hospital in Hartford, where he served as medical director between 2007 and 2021. He is currently the physician executive for the orthopedic service line at Trinity Health of New England. He is on the staff of Saint Francis Hospital and a member of Advanced Orthopedics New England. In 2014, Dr. Schutzer and two colleagues, Ms. Steph Kelly and Ms. Maureen Geary, launched a consulting company, Novel Healthcare Solutions, whose mission is to establish effective and trusting business relationships between physicians and hospital partners—and then create orthopedic Centers of Excellence. Dr. Schutzer is also vice president and co-founder of Upswing Health, a health technology start-up whose charge is to help 10 million lives alleviate suffering from musculoskeletal pain by the end of 2023. 04:52 Why would competitive physician groups gang together? 09:02 “Even if you never … bundle, going through the implementation process … will yield incredible unrecognized value.” 10:19 “It demands an end-to-end care redesign process.” 11:40 “The value of a COE is really unquestionable.” 11:48 “For every dollar saved [in a COE], two-thirds was in the quality side, and one-third was in the price point.” 14:38 Slide deck discussing the definition of a COE and its seven building blocks.15:06 “I'm talking about business relationships between the physicians … these are the most fundamental [relationships].” 16:24 “It is all about trust.” 16:49 What is the most central issue as to why a COE does well or fails? 17:26 “It's not just data. It has to be actionable data because physicians naturally don't trust data.” 22:55 “Employers are definitely taking note to patient-reported outcomes.” 23:38 What is the seventh element that is necessary for a COE, and what is fundamental to that element? 24:28 Where will fee-for-service doctors be in 2 to 3 years? 25:46 “The only way that we can accrue the value that we deserve is through these types of relationships.” 26:12 “The supreme motivator is opportunity.” 28:03 How do physicians and providers begin a transformation of the marketplace they're in? 28:38 “What they need from us is product. They need products to disrupt the status quo.” 31:27 “The problem is that there are vendors who are working at the margin.” You can contact Dr. Schutzer at steve.schutzer@gmail.com and learn more at the Novel Healthcare Solutions website.   @SSchutzer of @THOfNewEngland discusses #centersofexcellence on this week's #healthcarepodcast. #healthcare #podcast #digitalhealth #healthtech Why would competitive physician groups gang together? @SSchutzer of @THOfNewEngland discusses #centersofexcellence on this week's #healthcarepodcast. #healthcare #podcast #digitalhealth #healthtech “It demands an end-to-end care redesign process.” @SSchutzer of @THOfNewEngland discusses #centersofexcellence on this week's #healthcarepodcast. #healthcare #podcast #digitalhealth #healthtech “The value of a COE is really unquestionable.” @SSchutzer of @THOfNewEngland discusses #centersofexcellence on this week's #healthcarepodcast. #healthcare #podcast #digitalhealth #healthtech “It's not just data. It has to be actionable data because physicians naturally don't trust data.” @SSchutzer of @THOfNewEngland discusses #centersofexcellence on this week's #healthcarepodcast. #healthcare #podcast #digitalhealth #healthtech “Employers are definitely taking note to patient-reported outcomes.” @SSchutzer of @THOfNewEngland discusses #centersofexcellence on this week's #healthcarepodcast. #healthcare #podcast #digitalhealth #healthtech Where will fee-for-service doctors be in 2 to 3 years? @SSchutzer of @THOfNewEngland discusses #centersofexcellence on this week's #healthcarepodcast. #healthcare #podcast #digitalhealth #healthtech How do physicians and providers begin a transformation of the marketplace they're in? @SSchutzer of @THOfNewEngland discusses #centersofexcellence on this week's #healthcarepodcast. #healthcare #podcast #digitalhealth #healthtech Recent past interviews: Click a guest's name for their latest RHV episode! Lisa Trumble, Jeb Dunkelberger, Dr Ian Tong, Mike Schneider, Peter Hayes, Paul Simms, Dr Steven Quimby, Dr David Carmouche (EP343), Christin Deacon, Gary Campbell, Kristin Begley, David Contorno (AEE17), David Contorno (EP339), Nikki King, Olivia Webb, Brandon Weber, Stacey Richter (INBW30), Brian Klepper (AEE16), Brian Klepper (EP335), Sunita Desai, Care Plans vs Real World (EP333), Dr Tony DiGioia, Al Lewis, John Marchica, Joe Connolly, Marshall Allen, Andrew Eye, Naomi Fried

Hospitals that perform bronchoscopies can reduce readmission rates by over half, and potentially lower costs, by adopting single-use flexible bronchoscopes. That's according to a new abstract that was submitted and presented at the recently completed CHEST 2021 annual meeting. The study examined the health outcomes of more than 14,000 patients who underwent a bronchoscopy procedure and found that sterile, single-use bronchoscopes reduced the re-admissions rate 53 percent, from 7.7 percent to 3.6 percent, compared with reusable bronchoscopes. Dr. Hudson Garrett joined Endoscopy Insights to discuss the findings. In our conversation, he talks about why readmission rates are such an important performance metric for hospitals, the key clinical findings he identified in looking at this data, and the larger quality-of-care and patient safety conversations taking place in healthcare. Garrett is an Ambu consultant.

People Get admitted and discharged from the hospital every day- What we don't want is to come back within 30 days of that last admission. Face it No one wants to be in the hospital and NO ONE wants to be back within 30 days of being discharged or at all! There's no place like home ! Lets keep you there by talking about which conditions are the ones that can cause the most readmissions and how to prevent that. And yes I do say Myocardial Infection not Infarction. Told you it's all me in all my glory ready or not I do not edit- I just upload. You get a very raw Joyce. Text or call 847-809-1214 for questions or comments. #advocate #privateadvocate

Artificial intelligence can transform healthcare -- and the medical profession may be behind the curve. Regina Barzilay joins Vasant Dhar in episode 9 of Brave New World to talk about how doctors, programmers and lawyers need to find a meeting point to make the revolution happen. Useful resources: 1. Regina Barzilay at MIT CSAIL and MIT J-Clinic. 2. A Deep Learning Approach to Antibiotic Discovery -- Regina Barzilay and others. 3. Toward robust mammography-based models for breast cancer risk -- Regina Barzilay and others. 4. Multi-Objective Molecule Generation using Interpretable Substructures -- Regina Barzilay and others. 5. Human and Artificial Intelligence in Healthcare -- Episode 4 of Brave New World (w Eric Topol). 6. Artificial Intelligence — The Revolution Hasn't Happened Yet -- Michael Jordan. 7. Intelligible Models for HealthCare: Predicting Pneumonia Risk and Hospital 30-day Readmission -- Rich Caruana and others.

FDA 连续批准2个CGRP受体拮抗剂治疗急性偏头痛NEJM 中国41家三甲医院参加的DIRECT-MT研究NEJM 连续发表2种脊髓侧索硬化症在研新疗法瑞美吉泮（rimegepant）降钙素基因相关肽（CGRP）受体位于疼痛信号通路、颅内动脉和肥大细胞中，其活化被认为在偏头痛的病理生理学中起着因果作用。例如，偏头痛发作时血清中CGRP水平升高。瑞美吉泮（rimegepant）是一种新型的口服、小分子血管舒张剂-CGRP受体拮抗剂。2020年2月，FDA批准瑞美吉泮用于治疗偏头痛急性发作。《随机对照研究：瑞美吉泮治疗急性偏头痛的3期临床研究》Lancet，2020年8月 (1)在这项双盲、随机、安慰剂对照、多中心的第三期试验中，纳入偏头痛病史≥1年的、偏头痛患者1466人，被随机分配接受瑞美吉泮口腔崩解片75mg 和安慰剂治疗。给药后2小时，瑞美吉泮口腔崩解片在止痛方面优于安慰剂（21%对11%，p

Amol, general internal medicine resident at the University of Toronto, and Nathan, general surgery resident at the University of Toronto, discuss 2 recent studies: Does it matter which hospital patients return to after surgery? A large retrospective cohort study showed that when post-operative patients are re-admitted to the same hospital where they had their surgery, ...The post Changing the Tune: Post-operative Readmission and Music as Perioperative Therapy appeared first on Healthy Debate.

Amol, general internal medicine resident at the University of Toronto, and Nathan, general surgery resident at the University of Toronto, discuss 2 recent studies: Does it matter which hospital patients return to after surgery? A large retrospective cohort study showed that when post-operative patients are re-admitted to the same hospital where they had their surgery, ... The post Changing the Tune: Post-operative Readmission and Music as Perioperative Therapy appeared first on Healthy Debate.

Matt and Ryan have returned once again to assail your ears with smut and silliness! Come inside to hear the boys talk about some new Pod friends, old Xbox friends and an Interview. Come in and check out the fantastic fun inside!! Music Credits: If I Was A Lesbian by Chad Fess and Jason Lee